Innate Pharma (IPHA) Cash & Equivalents (2017 - 2026)
Innate Pharma's Cash & Equivalents was $7.51 million in the quarter ended Jun 30, 2026, down 90.0% from $75.16 million a year earlier.
Powered by 
Analysis
Innate Pharma (IPHA) Cash & Equivalents (2017 - 2026) Analysis & Trends
As of Dec 31, 2025, Cash & Equivalents at Innate Pharma came in at $31.74 million, down 55.8% from the prior year.
- Cash & Equivalents has now declined for six consecutive years, with a five-year compound annual growth rate of -27.3% (years ended Dec 2020 to Dec 2025).
- In earlier years, Cash & Equivalents was $71.86 million in the year ended Dec 31, 2024 (-5.9%), $76.37 million in the year ended Dec 31, 2023 (-14.0%), $88.77 million in the year ended Dec 31, 2022 (-25.2%) and $118.69 million in the year ended Dec 31, 2021 (-24.0%).
- The figure for the quarter ended Jun 30, 2026 marks the lowest quarterly Cash & Equivalents in data going back to the quarter ended Dec 31, 2017.
- The year-over-year decline in Cash & Equivalents has ranged between 1.2% (the quarter ended Jun 30, 2025) and 90.0% (the quarter ended Jun 30, 2026) over the last five years.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,199.50 Bn | 1,168.08 Bn | 19.71 Bn | 8.95 Bn |
| 2 | Johnson & Johnson | 635.17 Bn | 555.03 Bn | 17.30 Bn | 16.91 Bn |
| 3 | AbbVie | 504.69 Bn | 477.85 Bn | 12.70 Bn | 6.57 Bn |
| 4 | Merck | 358.43 Bn | 312.86 Bn | 12.21 Bn | 6.85 Bn |
| 5 | Novartis Ag | 288.36 Bn | 252.75 Bn | 11.24 Bn | 7.62 Bn |
| 6 | Astrazeneca | 265.78 Bn | 239.54 Bn | 12.86 Bn | 4.90 Bn |
| 7 | Amgen | 237.46 Bn | 192.86 Bn | 7.24 Bn | 13.99 Bn |
| 8 | Gilead Sciences | 193.65 Bn | 167.76 Bn | 6.22 Bn | 3.18 Bn |
| 9 | Pfizer | 171.05 Bn | 118.00 Bn | 10.94 Bn | 976.00 Mn |
| 10 | Innate Pharma | 139.64 Mn | -67.56 Mn | - | 7.38 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 7.38 Mn |
| Dec 31, 2025 | 33.00 Mn |
| Jun 30, 2025 | 62.98 Mn |
| Dec 31, 2024 | 69.09 Mn |
| Jun 30, 2024 | 74.95 Mn |
| Dec 31, 2023 | 78.15 Mn |
| Jun 30, 2023 | 77.61 Mn |
| Dec 31, 2022 | 89.79 Mn |
| Jun 30, 2022 | 107.55 Mn |
| Dec 31, 2021 | 117.50 Mn |
| Jun 30, 2021 | 123.76 Mn |
| Dec 31, 2020 | 168.25 Mn |
| Jun 30, 2020 | 147.95 Mn |
| Dec 31, 2019 | 227.28 Mn |
| Dec 31, 2018 | 174.25 Mn |
| Dec 31, 2017 | 118.66 Mn |
API Access
Innate Pharma Cash & Equivalents API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=cash-and-equivalents&ticker=IPHA&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "cash-and-equivalents", "ticker": "IPHA", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=cash-and-equivalents&ticker=IPHA&period=max&api_key=YOUR_API_KEY");
const data = await res.json();